NasdaqGM - Delayed Quote • USD
BioAtla, Inc. (BCAB)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:13 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 4 | 5 | 4 | 5 |
| Avg. Estimate | -0.79 | -0.54 | -2.76 | -1.93 |
| Low Estimate | -1 | -0.6 | -2.78 | -2.14 |
| High Estimate | -0.71 | -0.44 | -2.74 | -1.78 |
| Year Ago EPS | -0.63 | -0.58 | -2.74 | -2.76 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 12/31/2022 | 3/31/2023 | 6/30/2023 | 9/30/2023 |
|---|---|---|---|---|
| EPS Est. | -0.7 | -0.63 | -0.64 | -0.8 |
| EPS Actual | -0.63 | -0.58 | -0.75 | -0.7 |
| Difference | 0.07 | 0.05 | -0.11 | 0.1 |
| Surprise % | 10.00% | 7.90% | -17.20% | 12.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Current Estimate | -0.79 | -0.54 | -2.76 | -1.93 |
| 7 Days Ago | -0.79 | -0.54 | -2.76 | -1.93 |
| 30 Days Ago | -0.79 | -0.65 | -2.76 | -2.55 |
| 60 Days Ago | -0.79 | -0.65 | -2.76 | -2.55 |
| 90 Days Ago | -0.79 | -0.65 | -2.76 | -2.55 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | BCAB | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -25.40% | -- | -- | 6.50% |
| Next Qtr. | 6.90% | -- | -- | 12.00% |
| Current Year | -0.70% | -- | -- | 5.30% |
| Next Year | 30.10% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 3/28/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/27/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 12/5/2023 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/8/2023 |
| Maintains | JP Morgan: Overweight to Overweight | 9/25/2023 |
| Maintains | JP Morgan: Overweight to Overweight | 8/2/2023 |
Related Tickers
STRO Sutro Biopharma, Inc.
3.4200
0.00%
VOR Vor Biopharma Inc.
1.6900
-0.59%
CGEM Cullinan Therapeutics, Inc.
25.30
+31.43%
ACHL Achilles Therapeutics plc
0.7600
-2.69%
IKNA Ikena Oncology, Inc.
1.3000
-0.76%
MRSN Mersana Therapeutics, Inc.
2.9400
+3.16%
LVTX LAVA Therapeutics N.V.
2.7300
+3.41%
ITOS iTeos Therapeutics, Inc.
10.80
+1.89%
ENTA Enanta Pharmaceuticals, Inc.
12.37
-0.88%
NUVB Nuvation Bio Inc.
2.6800
+2.29%